Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2025-07-24 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：公司章程（2025年7月）
Governance Information Classification · 100% confidence The document is titled "上海赛伦生物技术股份有限公司章程" which translates to "Articles of Association of Shanghai Serum Bio-Technology Co., Ltd." It contains detailed sections on company governance, shareholder rights, board structure, share issuance, capital changes, and other corporate governance matters. The content is focused on the company's internal rules, board and shareholder meeting procedures, rights and obligations of shareholders, and management responsibilities. There is no indication that this is an annual report, financial statement, earnings release, or any other financial or regulatory filing. Instead, it is a governance document outlining the company's constitution and operational rules. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, supporting a high confidence classification.
2025-07-24 Chinese
赛伦生物：募集资金管理制度（2025年7月）
Governance Information Classification · 95% confidence The document is a detailed internal policy or regulation document regarding the management, storage, and use of raised funds (募集资金) by Shanghai Sairen Biotechnology Co., Ltd. It outlines procedures, responsibilities, and compliance requirements related to fundraising and fund usage. The content is regulatory and procedural in nature, focusing on governance and compliance with laws and stock exchange rules. It does not contain financial statements, earnings data, or audit opinions. It is not an announcement or a brief summary but a comprehensive internal governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-24 Chinese
赛伦生物：关于取消监事会、变更经营范围、修订《公司章程》及修订和制定公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding corporate governance changes, including the cancellation of the supervisory board, amendments to the company's articles of association, changes in business scope, and revisions to governance systems. It includes detailed legal and regulatory references, specific articles of the amended company charter, and governance rules. The content focuses on governance structure, board and shareholder meeting rules, and compliance with laws and stock exchange regulations. There is no financial data, earnings information, or audit results presented. The document is not a report of financial results or an audit report but rather a formal announcement of governance changes and related corporate resolutions. Therefore, it fits best under the category of Governance Information (CGR).
2025-07-24 Chinese
赛伦生物：关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 first extraordinary general meeting (临时股东大会) of Shanghai Serum BioTech Co., Ltd. It includes information about the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data, earnings, or audit information presented. The document is not a report itself but a formal announcement and notice to shareholders about the meeting and voting procedures. It does not contain minutes or results of the meeting, nor is it a proxy solicitation document with detailed voting information. Given the content and length (3280 characters), it fits the category of a shareholder meeting notice, which aligns best with the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this document is a notice of the meeting and voting procedures rather than the solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI).
2025-07-24 Chinese
赛伦生物：董事、高级管理人员行为准则（2025年7月）
Governance Information Classification · 100% confidence The document is a detailed code of conduct and governance guidelines for the company's directors and senior management, including their duties, obligations, disclosure requirements, and meeting participation rules. It references company law, securities law, stock exchange listing rules, and internal company bylaws. The content focuses on governance practices, roles, responsibilities, and compliance rather than financial results or announcements. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a notice of voting results, nor a proxy statement, nor a regulatory filing of a different nature. The document is a governance-related internal rules and conduct code, which fits the definition of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, consistent with CGR filings.
2025-07-24 Chinese
赛伦生物：累积投票制实施细则（2025年7月）
Governance Information Classification · 95% confidence The document is titled as implementation rules for cumulative voting system for the election of directors at Shanghai Sairen Biotechnology Co., Ltd. It details governance procedures related to board elections, nomination, voting, and election results. There is no financial data, no mention of financial results, no audit information, no shareholder voting results announcement, and no regulatory filing or report publication. The content is focused on governance practices and internal rules regarding board elections, which fits the definition of Governance Information (CGR). The document length is 3241 characters, which is relatively short but contains substantive governance content, not just an announcement or summary. Therefore, the appropriate classification is Governance Information (CGR).
2025-07-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.